Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

TTravere Therapeutics, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
T

Travere Therapeutics, Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
Loading financials
Income statement waterfall. Revenue $169.58M. Net result −$34.8M. A thin axis line marks the loss-zone boundary.

Income statement waterfall. Green diagonal stripes add to the running result, red diagonal stripes subtract from it, and a thin axis line marks the loss-zone boundary.

  • Revenue: $169.58M. Running result $169.58M. FILSPARI: $141.08M. License: $8.23M. Tiopronin Products: $20.27M.
  • Cost of revenue: −$2.17M. Running result $167.41M.
  • Gross profit: $167.41M. Running result $167.41M.
  • Operating costs: −$163.46M. Running result $3.95M.
  • Operating income: $3.95M. Running result $3.95M.
  • Other expense: −$38.96M. Running result −$35M.
  • Pre-tax loss: −$35M. Running result −$35M.
  • Income tax benefit: $204K. Running result −$34.8M.
  • Net loss: −$34.8M. Running result −$34.8M.